It has been hypothesized that blood lipid levels might be associated with prostate cancer risk. The aim of the present study was to evaluate the association between serum total cholesterol, highdensity lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and prostate cancer risk in a cohort study among 2842 Dutch men. By the end of follow-up, 64 incident cases of prostate cancer were identified. Serum total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were evaluated as potential risk factors for prostate cancer using multivariable Cox proportional hazards regression models. These analyses were restricted to men who never used cholesterol-lowering drugs (2118 men, 43 cases). Higher total and higher LDL cholesterol were significantly associated with an increased risk of prostate cancer (hazards ratios (HR) and 95% confidence interval (CI) per mmol l À1 were 1.39 (95% CI 1.03-1.88) and 1.42 (95% CI 1.00-2.02), respectively). Similar results were observed for aggressive prostate cancer, whereas for nonaggressive prostate cancer a significant association with HDL cholesterol was found (HR 4.28, 95% CI 1.17-15.67). The results of this study suggest that blood lipid levels may influence risk of prostate cancer. However, the exact roles of different cholesterol fractions on prostate cancer aggressiveness should be further evaluated.
Introduction
Epidemiological studies suggest that lipid profiles in blood are associated with risk of prostate cancer. Although some studies indicated that high serum triglycerides, 1,2 low or high serum high-density lipoprotein (HDL) cholesterol 3, 4 and high total [3] [4] [5] [6] [7] [8] or low-density lipoprotein (LDL) cholesterol 3, 4 might contribute to the development or progression of prostate cancer, overall results are relatively scarce and inconclusive.
So far, few studies have assessed the relation between serum triglycerides and prostate cancer risk. 2, 9 A casecontrol study among 504 cases with prostate cancer and 565 controls with BPH found a positive association between serum triglycerides and prostate cancer risk (odds ratio (OR) 1.15, 95% confidence interval (CI) 1.00-1.32). 2 A recent, prospective study based on 29 364 Norwegian men (687 incident cases), however, did not confirm an association between serum triglycerides and risk of incident or fatal prostate cancer. 9 Cholesterol has also been regarded as a potential risk factor for prostate cancer. Although two case-control studies have suggested that hypercholesterolemia increases the risk of prostate cancer, 3, 5 most prospective studies did not find any association, [9] [10] [11] [12] [13] [14] [15] or suggested that risk of prostate cancer decreases with increasing cholesterol levels. 16, 17 Recent studies were able to examine risk of clinical subtypes of prostate cancer in relation to cholesterol levels. 4, [6] [7] [8] An association between total cholesterol levels and risk of high-grade prostate cancer was consistently reported, whereas for total or low-grade prostate cancer risk, results were inconsistent. 4, [6] [7] [8] Supportive evidence for the potential role of cholesterol in prostate cancer development has been provided by observations that cholesterol-lowering drugs (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly known as statins) might be inversely associated with risk of (advanced) prostate cancer. 4, [18] [19] [20] [21] A meta-analysis by Bonovas et al. 22 confirmed that use of statins lowers the risk of advanced prostate cancer (relative risk 0.77, 95% CI 0.64-0.93); however, no effect for total prostate cancer risk was found (relative risk 0.95, 95% CI 0.73-1.23). Others proposed that the cholesterol-lowering effects of statins might not be the only reason why these drugs are associated with reduced risk of advanced prostate cancer. 22 Direct pro-apoptotic and anti-inflammatory effects of statins are suggested to inhibit the development or progression of prostate cancer, independent of cholesterol. 23, 24 Furthermore, differences in PSA-screening patterns between statin users and non-users might be responsible for the observed associations. 18, 22 As results are conflicting and underlying mechanisms have to be elucidated, further research is needed to evaluate the effects of cholesterollowering drugs on prostate cancer prevention, whereas studies on serum cholesterol and other blood lipids should confirm whether these blood lipids itself are potential risk factors for prostate cancer.
As described above, the relation between blood lipid profiles and prostate cancer risk has been previously investigated, but only few recent, prospective and population-based studies have been reported. 4, [6] [7] [8] [9] The aim of the present study was to address the association between serum cholesterol, triglycerides and prostate cancer risk in a prospective, population-based study from the Netherlands.
Materials and methods
The Nijmegen Biomedical Study is a survey of the general population in which a random, age-and sexstratified sample was recruited among adult inhabitants of Nijmegen, Lent and Oosterhout (eastern part of the Netherlands) between 2001 and 2003. The study was approved by the Institutional Review Board, and all participants provided written informed consent. In total, 21 756 inhabitants received an invitation to participate in this study. Of these, 9350 (43%) subjects agreed to participate, and filled out a postal questionnaire on lifestyle and medical history at baseline. Majority of the participants (90%) were Caucasian. Furthermore, 6468 (69%) participants donated two non-fasting blood samples, which were collected in tubes containing heparin (8.5 ml) or EDTA (8.5 ml). Blood samples were processed within 2 h after withdrawal and aliquots of serum were stored at À40 1C. All analyses of blood lipid profiles were performed between October 2004 and April 2005. Levels of serum total cholesterol, HDL cholesterol and triglycerides were analyzed enzymatically using an Abbott Aeroset autoanalyzer (Abbott Diagnostics, Hoofddorp, the Netherlands). Levels of LDL cholesterol were estimated using the Friedewald formula. 25 As the Friedewald formula appears to be accurate only up to triglyceride levels of 4.52 mmol l À1 , 25 we did not calculate LDL levels for participants with triglyceride levels above 4.52 mmol l À1 (n ¼ 132). All 3050 male participants of the Nijmegen Biomedical Study who provided blood samples were initially included in our analyses. Of these, 36 participants were excluded because they had a diagnosis of prostate cancer before blood withdrawal, 160 participants were excluded because no blood lipid measurements were available and another 12 participants were excluded because of incomplete follow-up data, leaving 2842 cohort members for final analyses. Cases of incident prostate cancer (n ¼ 64) were identified through record linkage with the Dutch population-based cancer registry. Follow-up duration was defined as the day of blood withdrawal until date of death, emigration, prostate cancer diagnosis or the end of follow-up (31 December 2009), whichever came first.
Information on age, height, weight, smoking status (current, former, never), history of hypertension (yes, no), history of diabetes mellitus (yes, no) and use of cholesterol-lowering drugs (current, former, never) were obtained from the self-reported questionnaires. For the prostate cancer cases, date of diagnosis, clinical and pathological stage (TNM, based on the 2002 American Joint Committee on Cancer guidelines 26 ), Gleason score (from biopsy or radical prostatectomy specimen) and PSA levels were obtained through the cancer registry, whenever available.
Cox proportional hazards regression analysis was used to calculate hazard ratios (HR) and 95% CI for prostate cancer risk. In order to attenuate any distorting effect of cholesterol-lowering drugs, these analyses were restricted to men who never used cholesterol-lowering drugs (cohort n ¼ 2118, cases n ¼ 43). Age (continuous), body mass index (continuous), and self-reported history of diabetes mellitus were included in the multivariable Cox model, because these factors were previously shown to be associated with prostate cancer risk 27, 28 and substantially (410%) affected the effect estimates in our analyses. Each blood lipid was evaluated individually as a continuous parameter (per mmol l À1 ). Although the number of cases is relatively small, we aimed to repeat the analyses for non-aggressive and aggressive prostate cancer separately. Non-aggressive prostate cancer is defined as a clinical or pathological stage T1 or T2, no evidence of positive lymph nodes (N0, NX) or metastases (M0, MX), Gleason score o7 and prediagnostic PSA levels o20 ng ml
À1
. Aggressive prostate cancer is defined as a clinical or pathological stage T3 or T4, N1, M1, Gleason score X7 or prediagnostic PSA levels X20 ng ml
. The Statistical Package of Social Sciences (SPSS, version 17.0, Chicago, IL, USA) was used for all statistical analyses.
Results
Baseline characteristics of the participants are presented in Table 1 . Among 2842 participants, 64 incident prostate cancer cases were identified during a median (interquartile range (IQR)) follow-up of 79.5 (IQR: 74.0-83.1) months. The median time between blood withdrawal and diagnosis of prostate cancer was 43.7 (IQR: 20.0-66.8) months. Cases were slightly older compared with cohort members. Median serum levels of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides appear to be fairly similar among the cohort members and the prostate cancer cases. After exclusion of participants who reported former or current use of cholesterol-lowering drugs (n ¼ 416) or with missing data on use of cholesterol-lowering drugs (n ¼ 308), 2118 cohort members and 43 cases were available for analyses. The participants who were excluded because of former or current use of cholesterol-lowering drugs (n ¼ 416) tended to be somewhat older, had a slightly higher body mass index and lower total and LDL cholesterol levels and were more likely to have a history of smoking, diabetes or hypertension compared with the participants Blood lipid levels and prostate cancer risk DEG Kok et al included in the analyses (data not shown). Of the 43 cases included in the analyses, 15 had a tumor with Gleason score o7, 20 cases had a Gleason score X7 and 8 cases had no data available for Gleason score. Tumor stage T1 or T2 was diagnosed in 27 cases, whereas T3 or T4 was found in 12 cases and 4 cases had an unknown tumor stage. Furthermore, six cases had positive lymph nodes (N1), 7 patients had distant metastasis (M1) and 15 patients had PSA levels X20 ng ml À1 (data not shown). As shown in Table 2 
Discussion
In this prospective, population-based study, we evaluated the association between blood lipid profiles and prostate cancer risk. We found that high levels of both total cholesterol and LDL cholesterol were associated with an increased risk of total and aggressive prostate cancer. In contrast, high levels of HDL cholesterol were associated with an increased risk of non-aggressive prostate cancer, whereas triglycerides were not statistically significantly associated with prostate cancer risk. It has previously been suggested that associations between blood lipid profiles and prostate cancer risk depend on the aggressiveness of the disease. 4, [6] [7] [8] Platz et al. 6 evaluated the association between plasma total cholesterol and prostate cancer risk in a casecontrol study nested in the Health Professionals FollowUp Study. Low total cholesterol levels (in the bottom quartile) were not associated with total prostate cancer risk (OR 0.93; 95% CI 0.72-1.20), however, those participants with low total cholesterol levels had a lower risk of high-grade prostate cancer (OR 0.61; 95% CI 0.39-0.98). 6 Subsequent prospective studies confirmed an association between levels of cholesterol and highgrade prostate cancer. 7, 8 Consistent with these results, we found a positive association between total cholesterol and aggressive prostate cancer risk. Next to aggressive disease, however, we also observed a modest association for total prostate cancer risk. Farwell et al. 4 presented similar findings from a retrospective cohort study in which total cholesterol was associated with total and high-grade prostate cancer risk.
The findings from our study suggest that increased levels of serum LDL cholesterol might be positively associated with total or aggressive prostate cancer risk. Studies focussing on the association between levels of LDL cholesterol and prostate cancer risk are relatively scarce. A hospital-based, case-control study suggested that high levels of LDL cholesterol (OR 1.60, 95% CI 1.09-2.34), but also total cholesterol (OR 1.58, 95% CI 1.11-2.24) and low levels of HDL cholesterol (OR 1.57, 95% CI 1.04-2.36), increase the risk of prostate cancer. 3 In the cohort of Farwell et al., 4 LDL cholesterol in the highest quartiles was statistically significantly associated with total and high-grade prostate cancer. Our results with respect to LDL cholesterol need to be interpreted with some caution, as non-fasting blood samples were used. The Friedewald formula for calculating levels of LDL cholesterol is based on the assumption that total cholesterol minus HDL and very-low-density lipoprotein cholesterol equals LDL cholesterol. 25 This method requires measurements of total cholesterol, HDL cholesterol and triglycerides (as a proxy for very-low-density lipoprotein cholesterol) levels. 25 Using non-fasting samples might result in high levels of triglycerides, a subsequent overestimation of very-low-density lipoprotein cholesterol and therefore might underestimate levels of LDL cholesterol. 29 In our cohort, 132 cohort members had non-fasting triglyceride levels above 4.52 mmol l À1 , which is suggested as the upper level for accurate Friedewald calculations. 25 For these 132 cohort members, we did not calculate levels of LDL cholesterol. Nevertheless, use of the Friedewald formula for non-fasting blood samples remains controversial. 30, 31 Although we assume that the non-fasting state is not different between men who later develop prostate cancer and men who do not, its possible role as source of bias should be considered when interpreting the results. Most likely, a non-differential underestimation of LDL cholesterol might result in a bias toward the null, that is, an underestimation of the HR for LDL cholesterol.
In contrast to total cholesterol and LDL cholesterol, the effects of HDL cholesterol were most pronounced for non-aggressive prostate cancer, that is, the results suggest that men with high levels of HDL cholesterol are at increased risk of developing non-aggressive prostate cancer. Similar findings were presented by Farwell et al., 4 who described a statistically significant association between HDL cholesterol (as continuous measure) and total and low-grade prostate cancer, whereas for high-grade prostate cancer the association did not reach statistical significance. However, detailed analyses with quartiles of HDL cholesterol did show statistically significant associations with high-grade prostate cancer risk. Other studies on HDL cholesterol and prostate cancer risk are inconclusive. Hammersten et al.
1 evaluated features of the metabolic syndrome among 299 patients recently diagnosed with prostate cancer. Subjects with poorly differentiated prostate cancer had lower HDL cholesterol levels and higher triglyceride levels compared with those with welldifferentiated disease.
1 A hospital-based, case-control study found a statistically significant association between low levels of HDL cholesterol and total prostate cancer risk. 3 Large prospective studies, however, did not consistently confirm an association between HDL cholesterol and localized, advanced or total prostate cancer risk. 9, 15 Our findings might be explained by several factors. First, high levels of HDL cholesterol may be associated with a healthy lifestyle. 32 In theory, participants with a healthy lifestyle, and consequently high HDL levels, may on average be more health conscious and may have consulted their physicians for periodic PSA testing. As a result, more early-stage prostate cancers might have been diagnosed among these men compared with other men in the cohort. Second, the positive association between HDL cholesterol and nonaggressive prostate cancer may be a chance finding, resulting from the relatively small number of cases.
The mechanisms underlying the possible association between blood lipid profiles and prostate cancer risk are poorly understood, but are possibly related to signaling functions of cholesterol. Cholesterol is incorporated into moving platforms in the fluid bilayer of cellular membranes, which are referred to as lipid rafts. 33 As reviewed by others, [34] [35] [36] these lipid rafts might have an important role in cell signaling (such as the EGFR/ Akt1 37 or IL6/STAT3 38 pathways), and could thereby act on growth and survival of prostate cancer cells. 37, 38 Future experiments focusing on lipid rafts should elucidate these and other signaling networks and their effects with respect to prostate cancer development or progression. Another hypothesis is based on the theory of steroidogenesis, which postulates that prostate cancer cells itself might be able to produce androgens, which can bind to the androgen receptor and stimulate growth and survival. 39 It has recently been shown that prostate cancer cells in advanced stages can synthesize androgens directly from cholesterol. 40 These findings might explain the suggested association between serum cholesterol levels and risk of aggressive forms of prostate cancer. Future studies are needed to confirm the exact role of cholesterol and other blood lipids in the development and progression of prostate cancer.
Unfortunately, because of the relatively small number of cases in our cohort, we were not able to perform Blood lipid levels and prostate cancer risk DEG Kok et al extensive analyses based on different tumor characteristics such as Gleason grade or tumor stage. Instead we used a rather arbitrary, combined definition of prostate cancer aggressiveness. It should be noted that only 69% of the participants of the Nijmegen Biomedical Study was willing to provide blood samples. Although we aimed at recruiting a random, population-based sample, we cannot exclude the possibility that only specific subgroups of participants agreed to provide blood samples. Although this selection is not an issue for the validity of the study, in theory, it may be so for the generalizability. Other potential limitations of the present study were the non-fasting blood samples as discussed previously, the relatively short follow-up (median 79.5 months) and the incapability to adjust for other potential confounders such as family history or socioeconomic status. Strengths of this study are the prospective design and the analyses of several blood lipid fractions in blood samples from a population-based cohort.
In conclusion, this study provides further evidence that blood lipid levels are associated with prostate cancer risk. Furthermore, our results suggest that different fractions of cholesterol are involved in aggressive and non-aggressive prostate cancer. The associations between the different fractions of cholesterol and clinical subtypes of prostate cancer warrant confirmation in larger, prospective studies.
Conflict of interest
The authors declare no conflict of interest.
